Compare Aterian Inc (ATER) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aterian Inc vs Gilead Sciences, Inc. — how do they compare? Aterian Inc trades at $0.48 (market cap $5.32M), while Gilead Sciences, Inc. trades at $135.34 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 31644.7× Aterian Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Aterian Inc pays none. Which is the better fit depends on your goals.
| ATER | GILD | |
|---|---|---|
Market Cap | $5.32M | $168.35B |
Sector | Consumer Cyclical | Health |
52-Week High | $1.39 | $155.80 |
52-Week Low | $0.36 | $110.56 |
Enterprise Value | $5.90M | $191.42B |
Dividend Yield | — | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aterian Inc
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
